The estimated Net Worth of Cynthia J Ladd is at least $768 mil dollars as of 6 January 2020. Cynthia Ladd owns over 1,849 units of MyoKardia stock worth over $641,218 and over the last 9 years Cynthia sold MYOK stock worth over $126,564.
Sign up
Cynthia Ladd MYOK stock SEC Form 4 insiders trading
Cynthia has made over 3 trades of the MyoKardia stock since 2015, according to the Form 4 filled with the SEC. Most recently Cynthia sold 1,849 units of MYOK stock worth $126,564 on 6 January 2020.
The largest trade Cynthia's ever made was exercising 4,700 units of MyoKardia stock on 1 January 2020 worth over $1,057,077. On average, Cynthia trades about 1,194 units every 204 days since 2015. As of 6 January 2020 Cynthia still owns at least 2,851 units of MyoKardia stock.
You can see the complete history of Cynthia Ladd stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cynthia Ladd's mailing address?
Cynthia's mailing address filed with the SEC is C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr y Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Cynthia Ladd stock trades at CytomX Therapeutics Inc y MyoKardia
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,